ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 941,64
0,88%
Dow Jones
44 796,47
0,19%
DAX
21 727,20
0,48%
Brent Oil
75,93
0,01%
Bitcoin
105 172,75
1,38%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Aclaris Therapeutics Inc (ACRS) Cours

Aclaris Therapeutics Inc

Aclaris Therapeutics Inc (ACRS)

NASDAQ
2,40
0,04
( 1,69% )
Mis à jour : 18:18:58
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
2,40
Prix Achat
2,39
Prix Vente
2,40
Volume échangé
69 424
2,3391 Fourchette du Jour 2,40
0,9515 Plage de 52 semaines 5,17
Cap du marché
171,434M
Clôture Veille
2,36
Ouverture
2,37
Dernière Transaction
1
@
2.397
Dernière heure de transaction
18:19:08
Volume financier
US$ 164 392
VWAP
2,3679
Volume moyen (3 m)
2 724 943
Actions en circulation
71 430 942
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-1,93
Bénéfice par action (BPA)
-1,24
Chiffre d'affairess
31,25M
Bénéfice net
-88,48M

À propos de Aclaris Therapeutics Inc

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from... Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.aclaristx.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Aclaris Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker ACRS. Le dernier cours de clôture d'Aclaris Therapeutics était de US$2,36. Au cours de la dernière année, les actions de Aclaris Therapeutics ont été négociées dans une fourchette de prix de US$ 0,9515 à US$ 5,17.

Aclaris Therapeutics compte actuellement 71 430 942 actions en circulation. La capitalisation boursière d'Aclaris Therapeutics est de US$168,58 million. Aclaris Therapeutics a un ratio cours/bénéfice (ratio PE) de -1.93.

ACRS Dernières nouvelles

Plus de nouvelles

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug...

06 Janvier 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

04 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 Janvier 2025
Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness

02 Janvier 2025
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

31 Décembre 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

19 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

12 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

06 Décembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.18-6.976744186052.582.582.285399092.42635448CS
4-0.1-42.52.7952.288986092.50260703CS
120.135.72687224672.275.172.0327249433.70598981CS
261.0780.45112781951.335.171.1214836123.26537259CS
521.1795.12195121951.235.170.951512018192.48964777CS
156-7.95-76.811594202910.3518.95830.590211992254.60855768CS
2601.0577.77777777781.3530.3750.590210572337.6006117CS

ACRS - Frequently Asked Questions (FAQ)

What is the current Aclaris Therapeutics share price?
The current share price of Aclaris Therapeutics is US$ 2,40
How many Aclaris Therapeutics shares are in issue?
Aclaris Therapeutics has 71 430 942 shares in issue
What is the market cap of Aclaris Therapeutics?
The market capitalisation of Aclaris Therapeutics is USD 168,58M
What is the 1 year trading range for Aclaris Therapeutics share price?
Aclaris Therapeutics has traded in the range of US$ 0,9515 to US$ 5,17 during the past year
What is the PE ratio of Aclaris Therapeutics?
The price to earnings ratio of Aclaris Therapeutics is -1,93
What is the cash to sales ratio of Aclaris Therapeutics?
The cash to sales ratio of Aclaris Therapeutics is 5,46
What is the reporting currency for Aclaris Therapeutics?
Aclaris Therapeutics reports financial results in USD
What is the latest annual turnover for Aclaris Therapeutics?
The latest annual turnover of Aclaris Therapeutics is USD 31,25M
What is the latest annual profit for Aclaris Therapeutics?
The latest annual profit of Aclaris Therapeutics is USD -88,48M
What is the registered address of Aclaris Therapeutics?
The registered address for Aclaris Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Aclaris Therapeutics website address?
The website address for Aclaris Therapeutics is www.aclaristx.com
Which industry sector does Aclaris Therapeutics operate in?
Aclaris Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
FOXXFoxx Development Holdings Inc
US$ 8,7999
(204,49%)
14,83M
AMODAlpha Modus Holdings Inc
US$ 3,8299
(148,69%)
108,53M
TECXTectonic Therapeutic Inc
US$ 56,3925
(119,26%)
4,03M
ACONAclarion Inc
US$ 17,9505
(94,85%)
1,56M
ATHEAlterity Therapeutics Limited
US$ 4,5906
(57,75%)
19,65M
CLEUChina Liberal Education Holdings Ltd
US$ 0,21
(-97,29%)
134,16M
CRGXCARGO Therapeutics Inc
US$ 3,4006
(-74,22%)
15,66M
FATFAT Brands Inc
US$ 3,385
(-42,33%)
173,31k
EVTVEnvirotech Vehicles Inc
US$ 0,3931
(-41,06%)
2,76M
ZKINZK International Group Co Ltd
US$ 0,30
(-38,21%)
1,69M
NVDANVIDIA Corporation
US$ 119,8519
(-3,11%)
188,34M
MGOLMGO Global Inc
US$ 0,11845
(16,47%)
140,18M
CLEUChina Liberal Education Holdings Ltd
US$ 0,21
(-97,29%)
134,97M
AMODAlpha Modus Holdings Inc
US$ 3,8299
(148,69%)
108,53M
SPGCSacks Parente Golf Inc
US$ 0,7733
(31,07%)
103,03M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
ACRS
Aclaris Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces